Hormonal Secretion and Quality Of Life in Nelson Syndrome and Cushing Disease After Long Acting Repeatable Octreotide

Authors:
  • ECEstela M. L. Cardoso
    Estela M. L. Cardoso
  • OSOlga B. Sandoval
    Olga B. Sandoval
  • ETElida G. Monardes Tumilasci
    Elida G. Monardes Tumilasci
  • RSRocío Sanchez
    Rocío Sanchez
  • LCLiliana N. Contreras
    Liliana N. Contreras
Publisher website
Google Scholar
Abstract
Clinical management of persistent adrenocorticotropin hormone (ACTH) excess in Nelson syndrome (NS) and Cushing disease (CD) remains a challenge. Somatostatin and its analogs as octreotide decrease ACTH secretion through somatostatin receptors of pituitary cells. To our knowledge, there are no reports on the effect of long-acting repeatable octreotide (oct-lar) on hormonal secretion and quality of life in patients with NS and CD who failed conventional therapy. Herein, we describe the effects of treatment with oct-lar (20 mg/month intramurally) in 1 woman with NS and 2 women with persistent CD. Oct-lar therapy reduced ACTH secretion and improved the quality of life in NS patient. By contrast, in CD patients, it failed to control ACTH and cortisol secretion, and the quality of life remained unchanged.

This publication has 19 references indexed in Scilit: